Stemergie's cancer stem cell (CSC) based technology platform allows the identification, validation and development of treatments for brain cancer. Stemergie has identified two novel molecular targets for brain CSC and is validating two compounds that specifically eradicate brain CSC. The company was liquidated in 2017.